Arrowstreet Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $285M | Buy |
638,950
+45,003
| +8% | +$21M | 0.15% | 126 |
|
|
2025
Q4 | $269M | Buy |
593,947
+212,752
| +56% | +$91.7M | 0.16% | 137 |
|
|
2025
Q3 | $149M | Buy |
381,195
+319,725
| +520% | +$134M | 0.09% | 206 |
|
|
2025
Q2 | $27.4M | Buy |
+61,470
| New | +$28.3M | 0.02% | 590 |
|
|
2025
Q1 | – | Sell |
-9,265
| Closed | -$3.73M | – | 2032 |
|
|
2024
Q4 | $3.73M | Buy |
+9,265
| New | +$4.29M | ﹤0.01% | 1094 |
|
|
2023
Q1 | – | Sell |
-5,233
| Closed | -$1.51M | – | 1546 |
|
|
2022
Q4 | $1.51M | Buy |
5,233
+141
| +3% | +$43K | ﹤0.01% | 941 |
|
|
2022
Q3 | $1.47M | Sell |
5,092
-4,698
| -48% | -$1.35M | ﹤0.01% | 917 |
|
|
2022
Q2 | $2.76M | Buy |
+9,790
| New | +$2.62M | ﹤0.01% | 710 |
|
|
2022
Q1 | – | Sell |
-24,249
| Closed | -$5.33M | – | 1557 |
|
|
2021
Q4 | $5.33M | Buy |
+24,249
| New | +$4.72M | 0.01% | 800 |
|
|
2021
Q3 | – | Sell |
-324,105
| Closed | -$65.3M | – | 1890 |
|
|
2021
Q2 | $65.3M | Buy |
324,105
+106,544
| +49% | +$22.3M | 0.08% | 271 |
|
|
2021
Q1 | $46.8M | Sell |
217,561
-173,238
| -44% | -$38.1M | 0.06% | 314 |
|
|
2020
Q4 | $92.4M | Buy |
390,799
+294,786
| +307% | +$67.6M | 0.13% | 140 |
|
|
2020
Q3 | $26.1M | Buy |
96,013
+13,431
| +16% | +$3.71M | 0.04% | 456 |
|
|
2020
Q2 | $24M | Buy |
82,582
+12,406
| +18% | +$3.36M | 0.04% | 435 |
|
|
2020
Q1 | $16.7M | Buy |
+70,176
| New | +$16.1M | 0.05% | 340 |
|
|
2019
Q4 | – | Sell |
-3,436
| Closed | -$582K | – | 1933 |
|
|
2019
Q3 | $582K | Sell |
3,436
-704,946
| -100% | -$125M | ﹤0.01% | 1291 |
|
|
2019
Q2 | $130M | Sell |
708,382
-133,127
| -16% | -$23.3M | 0.29% | 83 |
|
|
2019
Q1 | $155M | Buy |
841,509
+49,336
| +6% | +$9.11M | 0.37% | 54 |
|
|
2018
Q4 | $131M | Sell |
792,173
-9,694
| -1% | -$1.68M | 0.34% | 70 |
|
|
2018
Q3 | $155M | Sell |
801,867
-1,073,366
| -57% | -$191M | 0.35% | 73 |
|
|
2018
Q2 | $319M | Sell |
1,875,233
-249,983
| -12% | -$38.8M | 0.78% | 27 |
|
|
2018
Q1 | $346M | Buy |
2,125,216
+921,995
| +77% | +$151M | 0.79% | 27 |
|
|
2017
Q4 | $180M | Buy |
1,203,221
+570,287
| +90% | +$84.4M | 0.43% | 60 |
|
|
2017
Q3 | $96.2M | Buy |
632,934
+608,934
| +2,537% | +$91.7M | 0.26% | 95 |
|
|
2017
Q2 | $3.09M | Sell |
24,000
-48,800
| -67% | -$5.87M | 0.01% | 566 |
|
|
2017
Q1 | $7.96M | Buy |
+72,800
| New | +$6.41M | 0.03% | 448 |
|
|
2016
Q4 | – | Sell |
-5,500
| Closed | -$480K | – | 2531 |
|
|
2016
Q3 | $480K | Buy |
+5,500
| New | +$520K | ﹤0.01% | 1266 |
|
|
2016
Q2 | – | Sell |
-25,300
| Closed | -$2.01M | – | 1524 |
|
|
2016
Q1 | $2.01M | Buy |
+25,300
| New | +$2.29M | 0.01% | 811 |
|
|
2015
Q4 | – | Sell |
-47,784
| Closed | -$4.98M | – | 1611 |
|
|
2015
Q3 | $4.98M | Sell |
47,784
-317,639
| -87% | -$40.8M | 0.02% | 527 |
|
|
2015
Q2 | $45.1M | Buy |
365,423
+184,958
| +102% | +$23.3M | 0.26% | 103 |
|
|
2015
Q1 | $21.3M | Buy |
180,465
+177,483
| +5,952% | +$21.3M | 0.13% | 178 |
|
|
2014
Q4 | $354K | Buy |
+2,982
| New | +$336K | ﹤0.01% | 1097 |
|
|
2014
Q2 | – | Sell |
-233,978
| Closed | -$16.5M | – | 1191 |
|
|
2014
Q1 | $16.5M | Buy |
+233,978
| New | +$18.5M | 0.1% | 201 |
|
|
2013
Q4 | – | Sell |
-262,051
| Closed | -$19.9M | – | 1302 |
|
|
2013
Q3 | $19.9M | Sell |
262,051
-979
| -0.4% | -$77.9K | 0.13% | 175 |
|
|
2013
Q2 | $21M | Buy |
+263,030
| New | +$19.4M | 0.16% | 138 |
|
Other funds holding VRTX
VCM
VPM
Arrowstreet Capital's VRTX Position: Q1 2026 in Review
Arrowstreet Capital increased its Vertex Pharmaceuticals (VRTX) stake by 7.6% in Q1 2026, buying an estimated $21M and bringing the position to 638,950 shares worth $285M. The position accounts for 0.15% of the portfolio, ranked #126.
Arrowstreet Capital first reported a position in VRTX in Q2 2013 and has held it in 35 quarters since. The position peaked at $346M in Q1 2018. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Arrowstreet Capital held 638,950 shares of Vertex Pharmaceuticals worth $285M as of Q1 2026.
- Arrowstreet Capital bought 45,003 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21M.
- Vertex Pharmaceuticals made up 0.15% of Arrowstreet Capital's portfolio in Q1 2026, its #126 holding.
- Arrowstreet Capital first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
- Arrowstreet Capital's Vertex Pharmaceuticals position peaked at $346M in Q1 2018.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.